# Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-reports-first-quarter-2026-financial-results
Ticker: NBIX
Company: Neurocrine Biosciences
Source: Neurocrine Biosciences
Published: 2026-05-05 20:01 EST
Original Source URL: https://neurocrine.gcs-web.com
## Summary

Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated

## Article Body
Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated
## Recent Company News
- 2026-06-03 12:30 EST — [Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-new-two-year-crenessityr-crinecerfont-data-on-key-clinical-and-patient-reported-outcome-measures-at-endo-2026) — Source: Neurocrine Biosciences
- 2026-05-26 20:01 EST — [Neurocrine Biosciences to Present at Upcoming Investor Conferences in June](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-june) — Source: Neurocrine Biosciences
- 2026-05-18 20:05 EST — [Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-presents-real-world-data-highlighting-functional-impact-of-mild-tardive-dyskinesia-severity-and-improvement-with-ingrezzar-valbenazine-capsules) — Source: Neurocrine Biosciences
- 2026-05-18 12:46 EST — [Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-completes-acquisition-of-soleno-therapeutics) — Source: Neurocrine Biosciences
- 2026-05-06 12:30 EST — [Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-publication-of-expert-recommendations-for-glucocorticoid-dose-reduction-after-initiating-crenessityr-crinecerfont-for-the-treatment-of-classic-congenital-adrenal-hyperplasia) — Source: Neurocrine Biosciences
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)